Pharma Focus America

Cosette Pharmaceuticals Finalizes Acquisition of Ambien® and Ambien CR® (Zolpidem Tartrate) Tablets from Sanofi US

Thursday, July 11, 2024

Cosette Pharmaceuticals, a US-based specialty pharmaceutical company, has completed the acquisition of Ambien® and Ambien CR® in the United States from Sanofi US.

Cosette, expressed enthusiasm about the addition to their portfolio, stating, “We are excited to integrate Ambien®, leveraging our capabilities in managing complex product acquisitions. This acquisition enhances our product lineup and underscores our dedication to ensuring continued access to high-quality medications for patients globally.”

According to IQVIA®, U.S. sales of Ambien® and Ambien CR® totaled $39 million in the 12 months leading up to April 2024.

Cosette has a track record of effectively acquiring and integrating products from various markets, including Japan, Europe, and the USA. Their strategic approach and industry expertise aim to streamline divestitures and product transitions, maintaining uninterrupted availability of essential medicines for millions of patients.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024